12 research outputs found
Reviews
No full textLisa Tyler. Writing and Healing: Toward an Informed Practice. (Charles M. Anderson and Marian M. MacCurdy, eds., 2000).
Fran Claggett. Revisioning Writers\u27 Talk: Gender and Culture in Acts of Composing. (Mary Ann Cain, 1995).
Bruce Novak. Tomorrow\u27s Children: A Blueprint for Partnership Education in the 21st Century. (Riane Eisler, 2000).
Neal Lerner. Stories from the Center: Connecting Narrative and Theory in the Writing Center. (Lynn Craigue Briggs and Meg Woolbright, eds., 2000)
William Claggett: A Printer Confirmed
No full textThis segment is the latest chapter on the life of William Claggett, clockmaker, engraver, scientist, and now, conclusively, printer. This article examines a newly-discovered document that confirms a long-held belief that Claggett printed money for the colony of Rhode Island on plates that he engraved. The author, Richard L. Champlin, is the former librarian at the Redwood Library and has studied the lives and work of Newport\u27s clockmakers for more than twenty years
NT-proBNP versus routine clinical risk factors as a predictor of cardiovascular events or death in people with dysglycemia & ndash : A brief report from the ORIGIN trial
No full textIn patients with diabetes and cardiovascular or renal comorbidities, circulating levels of the N-terminal fragment of prohormone B-type natriuretic peptide (NT-proBNP) have similar discriminatory ability as multivariate models for prediction of cardiovascular events or death. We validated this finding in patients with dysglycemia not selected for co-existing cardiorenal diseases. (c) 2021 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).</p
Author Correction: Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes
No full textInternational audienc
Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial
No full textInfluence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial
No full textAims: In GALACTIC-HF, the cardiac myosin activator omecamtiv mecarbil compared with placebo reduced the risk of heart failure events or cardiovascular death in patients with heart failure with reduced ejection fraction. We explored the influence of atrial fibrillation or flutter (AFF) on the effectiveness of omecamtiv mecarbil. Methods and results: GALACTIC-HF enrolled patients with New York Heart Association (NYHA) Class II-IV heart failure, left ventricular ejection fraction ≤35%, and elevated natriuretic peptides. We assessed whether the presence or absence of AFF, a pre-specified subgroup, modified the treatment effect for the primary and secondary outcomes, and additionally explored effect modification in patients who were or were not receiving digoxin. Patients with AFF (n = 2245, 27%) were older, more likely to be randomized as an inpatient, less likely to have a history of ischaemic aetiology or myocardial infarction, had a worse NYHA class, worse quality of life, lower estimated glomerular filtration rate, and higher N-terminal pro-B-type natriuretic peptide. The treatment effect of omecamtiv mecarbil was modified by baseline AFF (interaction P = 0.012), with patients without AFF at baseline deriving greater benefit. The worsening of the treatment effect by baseline AFF was significantly more pronounced in digoxin users than in non-users (interaction P = 0.007); there was minimal evidence of effect modification in those patients not using digoxin (P = 0.47) or in digoxin users not in AFF. Conclusion: Patients in AFF at baseline were less likely to benefit from omecamtiv mecarbil than patients without AFF, although the attenuation of the treatment effect was disproportionally concentrated in patients with AFF who were also receiving digoxin. Clinical Trial Registration: NCT02929329 © 2022 The Author(s) 2022
Finerenone Reduces New-Onset Atrial Fibrillation Across the Spectrum of Cardio-Kidney-Metabolic Syndrome: The FINE-HEART Pooled Analysis
No full textBackground: Mineralocorticoid receptor antagonists (MRA) modulate cardiac and systemic pathways such as fibrosis and inflammation, which may contribute to the onset of atrial fibrillation (AF) or atrial flutter (AFL). Objectives: In this participant-level pooled analysis of 3 large clinical trials, the authors evaluated the effect of the nonsteroidal MRA finerenone on incident AF/AFL across the cardio-kidney-metabolic (CKM) spectrum. Methods: In this prespecified analysis, we pooled participants from 2 trials of chronic kidney disease and type 2 diabetes (FIDELIO-DKD and FIGARO-DKD) and a trial of heart failure (HF) with mildly reduced or preserved ejection fraction (FINEARTS-HF). Patients were randomized 1:1 to finerenone or placebo. New-onset AF/AFL was prospectively adjudicated in all trials by blinded clinical event committees. The risk of new-onset AF/AFL was evaluated using Cox regression models stratified by region and trial. Results: Among 14,581 patients who were free of AF/AFL at trial enrollment, 631 (4.3%) experienced new-onset AF/AFL during follow-up. Predictors of new-onset AF/AFL included older age, history of HF, higher body mass index, geographic region, and higher levels of urine albumin-to-creatinine ratio. During 2.9 years of median follow-up, new-onset AF/AFL occurred in 286 (3.9%) participants receiving finerenone and 345 (4.7%) assigned to placebo (HR: 0.83; 95% CI: 0.71-0.97; P = 0.019). Risk reductions were consistent irrespective of number of CKM conditions (Pinteraction = 0.87) and by trial (Pinteraction = 0.57). Participants with new-onset AF/AFL were at significantly higher subsequent risk of cardiovascular death, HF hospitalization, and adverse kidney outcomes. Conclusions: The nonsteroidal MRA finerenone reduced the risk of new-onset AF/AFL across the CKM spectrum. © 2025 The Author
The efficacy of finerenone on hierarchical composite endpoint analysed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of FINEARTS-HF
No full textAims: FINEARTS-HF demonstrated the efficacy of finerenone in reducing total worsening heart failure (HF) events (first and recurrent) and cardiovascular death, compared to placebo, in patients with HF and mildly reduced or preserved ejection fraction. We examined the effect of finerenone on these events according to their clinical importance using win statistics. Methods and results: We developed a prespecified hierarchical composite endpoint including the components of the original primary outcome: cardiovascular death (tier 1), total HF hospitalizations (tier 2), and total urgent HF visits (tier 3). For tiers 2 and 3, the number of events was analysed first, followed by the time-to-first event. Because win statistics are affected by the censoring distribution, we assessed the hierarchical composite outcome over a fixed period of 24 months. The 6001 participants analysed were randomized equally to finerenone (n = 3003) or placebo (n = 2998). At 24 months, a total of 825 cardiovascular deaths and worsening HF events were observed in the finerenone group, compared with 1012 events in the placebo group. The win ratio was 1.17 (95% confidence interval [CI] 1.04–1.32) (p = 0.010), demonstrating more wins than losses in the finerenone group. The win odds, corresponding to the treatment effect, was 1.05 (95% CI 1.01–1.09), and the net benefit, corresponding to the absolute risk difference, was 2.6% (95% CI 0.6–4.5%). The win ratio remained above 1.0 from 60 days after randomization and reached a plateau after approximately 12 months. HF hospitalizations contributed more to the overall results than cardiovascular death. The win odds at 12 months was 1.04 (95% CI 1.01–1.08), and when adding the Kansas City Cardiomyopathy Questionnaire total symptom score to the hierarchical endpoint as a continuous variable, that increased to 1.07, which is almost identical to the win ratio due to the decrease in ties. Conclusion: Finerenone treatment led to a significant improvement in a composite hierarchical outcome that incorporated cardiovascular death, total HF hospitalizations, and total urgent HF visits, with early onset of benefit. Clinical Trial Registration: ClinicalTrials.gov ID NCT04435626. © 2025 The Author(s). European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology
Eyewitness accounts of 'the Indies' in the Later Medieval West: reading, reception, and re-use (c. 1300-1500)
No full textDespite increased mercantile and missionary contact between the Latin West and India and China between the thirteenth and fifteenth centuries, scholars have often
noted that Western Europe's knowledge of India, as judged by geographical texts from the period, changed surprisingly little during this time. This thesis employs
some of the methodologies of reception studies in order to investigate the role played by first-hand travel accounts in the construction and change of concepts of the Indies
during the fourteenth and fifteenth centuries. It investigates in particular the reception in Italy, France and England of the information about the area known as
India or the 'three Indies' presented in the texts produced by two Italian travellers to the East: the Divisament dou monde of the Venetian merchant Marco Polo (c. 1298),
and the Relatio of the Franciscan missionary Odorico da Pordenone (1330).
The thesis falls into three distinct parts. In the first section, I contextualise the project with a broad survey of the Latin European ideas of India in the late thirteenth
and early fourteenth centuries and with an outline of the travellers' journeys and their contexts. The second part of the thesis provides a broad overview of the
circumstances of diffusion of the two travel accounts in England, France and Italy over the fourteenth and fifteenth centuries, before conducting a detailed, manuscriptbased
investigation of the ways in which the two accounts of India were approached by their early readers. This investigation focuses principally upon the presentation
and possible modes of reception of the texts' geographical and ethnographic details and relies heavily on the evidence of presentation, paratext and the traces of reading
present in the physical texts of the accounts.
The third and final part of the thesis considers the evidence of the reception of elements from first-hand travel accounts in other textual and cartographic
productions. Proceeding on the basis of case studies, it demonstrates that first-hand accounts of 'the Indies' were used by the authors and compilers of cosmo graphical
texts in this period in a variety of ways. It suggests, however, that the manner and context of the deployment of elements from such accounts often tended to assimilate
these with, rather than distinguish them from, the writings of accepted authorities. This section also contrasts the way that details from travel accounts were re-used in
texts with the way the same information was handled in the composition of maps. Finally, by analysis of the ways eyewitness accounts of the Indies were re-used in
certain ambiguous and comic texts produced in this period, the thesis sheds light on an underexplored aspect of the reception both of eyewitness information and of the
genres in which it appeared. The appendices contain tables presenting information relative to the manuscripts discussed that support the arguments presented in section
two
